VERTEX PHARMACEUTICALS INC / MA·4

Feb 23, 4:21 PM ET

Sachdev Amit 4

4 · VERTEX PHARMACEUTICALS INC / MA · Filed Feb 23, 2026

Research Summary

AI-generated summary of this filing

Updated

Vertex (VRTX) EVP Amit Sachdev Exercises Options and Sells Shares

What Happened

  • Amit Sachdev, EVP, Chief Patient & External Affairs Officer at Vertex, exercised two option grants on 2026-02-19 to acquire 48,505 shares (23,479 at $155.57 = $3,652,628; 25,026 at $187.53 = $4,693,126; total cost ≈ $8,345,754).
  • The filing also reports multiple open‑market sales the same day totaling 58,613 shares sold for aggregate proceeds of $27,479,582 (individual sale prices ranged roughly $463.44–$472.03; weighted averages noted per line).
  • Two derivative lines show the option instruments were converted/terminated (reported as disposed at $0) in connection with the exercises. This pattern—exercise followed by same‑day sales—is effectively a cashless exercise and sale of the acquired shares.

Key Details

  • Transaction date: 2026-02-19; Form 4 filed 2026-02-23 (within the standard reporting window).
  • Exercises: 23,479 @ $155.57 ($3,652,628) and 25,026 @ $187.53 ($4,693,126).
  • Open‑market sales: 58,613 shares at prices from ~$463.44 to $472.03; total proceeds ≈ $27,479,582. One line’s weighted average noted as $471.43 (range $471.10–$472.03).
  • Shares owned after transaction: not specified in the filing.
  • Footnotes: trades were made under a company‑approved Rule 10b5‑1 plan entered 11/18/2025 (F1); options were fully vested (F11). The filer commits to providing a per‑price breakdown on request (F3).

Context

  • Because the exercises and sales occurred the same day and the derivative lines report $0 disposals, this is effectively a cashless exercise (exercise of options followed by sale of shares). Such activity is commonly driven by option exercise/tax-liability management rather than an expressed change in view on the company.
  • Trades were executed under a pre‑arranged 10b5‑1 trading plan, which typically means the sales were scheduled in advance. This is routine insider selling and not, by itself, evidence of new information about company fundamentals.

Insider Transaction Report

Form 4
Period: 2026-02-19
Sachdev Amit
EVP Chief Patient & Ext Af Off
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-19$155.57/sh+23,479$3,652,62892,521 total
  • Exercise/Conversion

    Common Stock

    2026-02-19$187.53/sh+25,026$4,693,126117,547 total
  • Sale

    Common Stock

    [F1][F2][F3]
    2026-02-19$463.91/sh920$426,797116,627 total
  • Sale

    Common Stock

    [F1][F3][F4]
    2026-02-19$465.05/sh2,730$1,269,587113,897 total
  • Sale

    Common Stock

    [F1][F3][F5]
    2026-02-19$465.80/sh1,848$860,798112,049 total
  • Sale

    Common Stock

    [F1][F3][F6]
    2026-02-19$467.75/sh10,263$4,800,518101,786 total
  • Sale

    Common Stock

    [F1][F3][F7]
    2026-02-19$468.57/sh19,662$9,213,02382,124 total
  • Sale

    Common Stock

    [F1][F3][F8]
    2026-02-19$469.61/sh7,241$3,400,44674,883 total
  • Sale

    Common Stock

    [F1][F3][F9]
    2026-02-19$470.54/sh11,712$5,510,96463,171 total
  • Sale

    Common Stock

    [F1][F3][F10]
    2026-02-19$471.43/sh4,237$1,997,44958,934 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F11]
    2026-02-1923,4790 total
    Exercise: $155.57Exp: 2028-02-05Common Stock (23,479 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F11]
    2026-02-1925,0260 total
    Exercise: $187.53Exp: 2029-02-05Common Stock (25,026 underlying)
Holdings
  • Common Stock

    (indirect: By 401(k))
    882
  • Common Stock

    (indirect: By Trust)
    9,301
Footnotes (11)
  • [F1]Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025.
  • [F10]Open market sales reported on this line occurred at a weighted average price of $471.43 (range $471.10 to $472.03).
  • [F11]Fully vested.
  • [F2]Open market sales reported on this line occurred at a weighted average price of $463.91 (range $463.44 to $464.28).
  • [F3]Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  • [F4]Open market sales reported on this line occurred at a weighted average price of $465.05 (range $464.48 to $465.46).
  • [F5]Open market sales reported on this line occurred at a weighted average price of $465.80 (range $465.54 to $466.49).
  • [F6]Open market sales reported on this line occurred at a weighted average price of $467.75 (range $467.09 to $468.05).
  • [F7]Open market sales reported on this line occurred at a weighted average price of $468.57 (range $468.10 to $469.09).
  • [F8]Open market sales reported on this line occurred at a weighted average price of $469.61 (range $469.10 to $470.05).
  • [F9]Open market sales reported on this line occurred at a weighted average price of $470.54 (range $470.10 to $471.08).
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-02-23

Documents

1 file
  • 4
    wk-form4_1771881700.xmlPrimary

    FORM 4